Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
Diabetic macular edema refers to swelling (fluid accumulation) in the center of the retina.
The retina is like the film of a camera and is located in the back of the eye. This condition
can develop in diabetics where swelling results from leaking of fluid from the blood vessels
of the eye, into the center of the retina, the macula. If left untreated, this can affect
central vision. The current standard treatment for diabetic macular edema includes
medications injected directly into the eye (intravitreal injections) and laser eye treatment.
The drugs that are injected directly into the eye are known as anti-Vascular Endothelial
Growth Factor (anti-VEGF) agents which help to reduce the leaking. However, response in
patients to these anti-VEGF drugs can vary and examination of predictive factors is required.
This particular study examines cellular factors called cytokines in patients receiving
aflibercept, a type of anti-VEGF drug, in the hopes of detecting changes in cytokines that
can predict treatment response amongst groups of patients.
Phase:
Phase 4
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto